{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:06:56Z","timestamp":1790165216332,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.rpth.2026.106899","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:55:53Z","timestamp":1785858953000},"page":"106899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibition of fibrinolysis in vitro by supraphysiological doses of small-molecule factor XIa inhibitors"],"prefix":"10.1016","volume":"10","author":[{"given":"Jelle","family":"Adelmeijer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3503-7140","authenticated-orcid":false,"given":"Ton","family":"Lisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106899_bib1","doi-asserted-by":"crossref","first-page":"27176","DOI":"10.1074\/jbc.273.42.27176","article-title":"A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor","volume":"273","author":"Wang","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.rpth.2026.106899_bib2","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1182\/blood.V86.8.3035.3035","article-title":"Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis","volume":"86","author":"von dem Borne","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106899_bib3","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1172\/JCI119412","article-title":"Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis","volume":"99","author":"Von dem Borne","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.rpth.2026.106899_bib4","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1182\/blood.V88.10.3815.bloodjournal88103815","article-title":"Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma","volume":"88","author":"Broze","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106899_bib5","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/jth.12600","article-title":"Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency","volume":"12","author":"Zucker","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106899_bib6","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1055\/s-0037-1616530","article-title":"The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration","volume":"86","author":"Mosnier","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106899_bib7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1182\/blood.V99.1.175","article-title":"Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A","volume":"99","author":"Lisman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106899_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100043","article-title":"Congruent identification of imbalanced fibrinolysis by 2 distinct clot lysis time assays","volume":"7","author":"Driever","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106899_bib9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11239-023-02837-3","article-title":"Profibrinolytic effects of rivaroxaban are mediated by thrombin-activatable fibrinolysis inhibitor and are attenuated by a naturally occurring stabilizing mutation in enzyme","volume":"56","author":"Garabon","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2026.106899_bib10","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1538-7836.2010.03739.x","article-title":"Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor","volume":"8","author":"Ammollo","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106899_bib11","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1055\/a-2497-4213","article-title":"Real-time imaging of platelet-initiated plasma clot formation and lysis unveils distinct impacts of anticoagulants","volume":"125","author":"Suzuki","year":"2025","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106899_bib12","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41569-025-01144-z","article-title":"Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism","volume":"22","author":"Capodanno","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.rpth.2026.106899_bib13","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acs.jmedchem.1c00613","article-title":"Discovery of milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy","volume":"65","author":"Dilger","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.rpth.2026.106899_bib14","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106899_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0006-291X(69)90278-2","article-title":"Activation of plasminogen by human plasma kallikrein","volume":"35","author":"Colman","year":"1969","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.rpth.2026.106899_bib16","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1016\/j.jtha.2025.06.016","article-title":"Effect of heparins, direct oral anticoagulants, and factor XII\/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: an in vitro study","volume":"23","author":"Hardy","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106899_bib17","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3390\/diagnostics14171991","article-title":"Laboratory evaluation of interferences associated with factor XIa inhibitors asundexian and milvexian in routine coagulation assays","volume":"14","author":"Buckley","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.rpth.2026.106899_bib18","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1016\/j.jtha.2025.05.032","article-title":"DOAC\u2013Stop reverses the anticoagulant effect of asundexian and milvexian","volume":"23","author":"Fitzpatrick","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106899_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bvth.2026.100139","article-title":"Screening chemical libraries for the development of oral treatments in bleeding disorders","volume":"3","author":"Zelli","year":"2026","journal-title":"Blood Vessel Thromb Hemost"},{"key":"10.1016\/j.rpth.2026.106899_bib20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00001721-199104000-00003","article-title":"Venous thrombosis and tissue plasminogen activator release deficiency: a family study","volume":"2","author":"Patrassi","year":"1991","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.rpth.2026.106899_bib21","article-title":"Tissue-type plasminogen activator (tPA) homozygous Tyr471His mutation associates with thromboembolic disease","volume":"4","author":"Tao","year":"2023","journal-title":"MedComm (2020)"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:50:19Z","timestamp":1790164219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926035570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2475037926035570"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106899","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of fibrinolysis in vitro by supraphysiological doses of small-molecule factor XIa inhibitors","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106899","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106899"}}